Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul;10(7):685-700.
doi: 10.1016/S2468-1253(25)00068-8. Epub 2025 May 20.

A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles

Lindsey Hiebert-Suwondo  1 , Jana Manning  2 , Rania A Tohme  3 , Maria Buti  4 , Loreta A Kondili  5 , C Wendy Spearman  6 , Behzad Hajarizadeh  7 , Victoria Turnier  2 , Jeffrey V Lazarus  8 , Jason Grebely  7 , Gregory J Dore  7 , Imam Waked  9 , John W Ward  2 ; National Hepatitis Elimination Profile Collaborators
Collaborators, Affiliations
Review

A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles

Lindsey Hiebert-Suwondo et al. Lancet Gastroenterol Hepatol. 2025 Jul.

Abstract

The Coalition for Global Hepatitis Elimination's National Hepatitis Elimination Profiles assess the status of national data, policy, and programme development for the elimination of viral hepatitis. To date, profiles from 33 countries and territories have been developed. These profiles reveal that 30 (91%) countries and territories have hepatitis C national action plans, 11 (33%) have systems to monitor hepatitis C-related mortality, 16 (48%) have systems to monitor hepatitis C incidence, and 18 (55%) have systems to track the number of people tested and treated. Some countries and territories continue to uphold barriers to hepatitis C treatment, with 12 (36%) still having partial or full restrictions on prescribing authority for non-specialists. Ten (30%) countries and territories have met the WHO 2025 diagnosis coverage target of 60%, five (15%) have met the treatment target of 50%, and seven (21%) have met the needle and syringe exchange target. Although there are examples of countries and territories across the income spectrum meeting these targets, policy development in low-income and middle-income countries and territories generally lags behind that in high-income countries and territories.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests CWS reports speaker honoraria from Gilead Sciences and Sanofi, and meeting travel support from Gilead Sciences. GJD reports research grants from Gilead Sciences and AbbVie. IW reports grants from Arena, AbbVie, and AstraZeneca, and honoraria from AstraZeneca and Roche. JG reports grants from AbbVie, bioLytical, Cepheid, Gilead Sciences, and Hologic, and honoraria from AbbVie, Abbott, Cepheid, Gilead Sciences, and Roche. JVL reports grants to his institutions from AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Madrigal, MSD, Novo Nordisk, Pfizer, Roche Diagnostics, and Moderna unrelated to this work. JVL reports consulting fees from Echosens, Novovax, GSK, Novo Nordisk, Pfizer, and Prosciento unrelated to this work. JVL received lecture honoraria from AbbVie, Echosens, Gilead Sciences, Janssen, Moderna, MSD, Novo Nordisk, and Pfizer unrelated to this work. JVL participates in an advisory board for the project entitled Same-visit hepatitis C testing and treatment to accelerate cure among people who inject drugs (The QuickStart Study): a cluster randomised control trial—Australia; is in an unpaid leadership role with Healthy Livers, Healthy Lives, and HIV Outcomes, and is also a committee co-chair for the Global NASH Council. LHS, JM, and JWW report grant support to the Task Force for Global Health for the general support of the CGHE from Abbott, AbbVie, Dynavax, Gilead, John C Martin Foundation, Merck, Open Philanthropy, Pharco, Roche, Siemens, US Centers for Disease Control and Prevention, and Zydus Lifesciences. LAK reports research grants to her institution from Gilead Sciences. MB reports grants and consulting fees from Gilead Sciences and honoraria payments from Gilead Sciences and AbbVie. All other authors declare no competing interests.

Figures

Figure 1:
Figure 1:. Map showing countries and territories with National Hepatitis Elimination Profiles
African region: Ethiopia, Ghana, Nigeria, Rwanda, Senegal, and South Africa. Region of the Americas: Argentina, Brazil, Canada, Colombia, Mexico, Peru, and the USA. Eastern Mediterranean region: Egypt and Pakistan. European region: England, Georgia, Italy, Portugal, Spain, Switzerland, and Ukraine. South-East Asia region: Bangladesh, Indonesia, Myanmar, and Thailand. Western Pacific region: Australia, China, Japan, South Korea, the Philippines, Taiwan, and Viet Nam.
Figure 2:
Figure 2:. Hepatitis C policy scores by income classification
(A) Hepatitis C mean policy scores for policy categories. (B) Mean total hepatitis C policy scores by income classification. (C) Country and territory hepatitis C policy scores. HCV=hepatitis C virus. *Two policies. †Five policies. ‡Four policies. §Seven policies. ¶One policy.
See this image and copyright information in PMC

References

    1. WHO. Global hepatitis report 2024. Action for access in low- and middle-income countries. 2024. https://www.who.int/publications/i/item/9789240091672 (accessed Dec 19, 2024).
    1. WHO. Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. 2022. https://iris.who.int/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.p... (accessed Sept 20, 2024).
    1. WHO. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030. 2022. https://iris.who.int/bitstream/handle/10665/360348/9789240053779-eng.pdf... (accessed Sept 20, 2024).
    1. WHO. Interim guidance for country validation of viral hepatitis elimination. 2021. https://iris.who.int/bitstream/handle/10665/341652/9789240028395-eng.pdf... (accessed Dec 19, 2024). - PubMed
    1. WHO. Guidance for country validation of viral hepatitis elimination and path to elimination. 2023. https://iris.who.int/bitstream/handle/10665/373186/9789240078635-eng.pdf... (accessed Dec 19, 2024).

Publication types

MeSH terms

Substances

LinkOut - more resources